Publications

21-Apr-2020

Jacobs MR, Good CE, Hujer AM, Abdelhamed AM, Rhoads DD, Hujer KM, Rudin SD, Domitrovic TN, Connolly LE, Krause KM, Patel R, Arias CA, Kreiswirth BN, Rojas LJ, D'Souza R, White RC, Brinkac LM, Nguyen K, Singh I, Fouts DE, van Duin D, Bonomo RA, Antibacterial Resistance Leadership Group

ARGONAUT II Study of the In Vitro Activity of Plazomicin against Carbapenemase-Producing Klebsiella pneumoniae.

Antimicrobial agents and chemotherapy. 2020-04-21; 64.5:

Plazomicin was tested against 697 recently acquired carbapenem-resistant isolates from the Great Lakes region of the United States. Plazomicin MIC and MIC values were 0.25 and 1 mg/liter, respectively; 680 isolates (97.6%) were susceptible (MICs of ≤2 mg/liter), 9 (1.3%) intermediate (MICs of 4 mg/liter), and 8 (1.1%) resistant (MICs of >32 mg/liter). Resistance was associated with -, -, or -encoded 16S rRNA methyltransferases in all except 1 isolate.

PMID: 32152078